Purpose: In cirrhotic livers reliable visualization and exact localization of small hepatocellular carcinoma (HCC) can be challenging without adequate contrast enhancement. To investigate the feasibility, technical success rate, and safety of hepatobiliary phase MRI-guided percutaneous radiofrequency ablation (RFA) of small HCCs invisible on precontrast MRI.
Methods: 53 patients (17f, 63.6 ± 16.7 years), with small HCC that were not visible in non-contrast MRI underwent MRI guided RFA. Feasibility was assessed by analyzing proper identification of the target tumor, tumor delineation during MRI-guided needle positioning and number of needle adjustments required for accurate placement. Technical success was defined as complete ablation with a safety margin of 5 mm. Safety was assessed from reports of procedure-related complications.
Results: In all 53 cases, target tumors were not visible in non-contrast MRI but in the hepatobiliary phase. In 5 cases, planning imaging showed new tumors, which were either treated in the same session (n = 4) or altered the therapeutic approach (n = 1). Mean tumor diameter was 9.7 ± 1.9 mm and the number of needle adjustments was 5 ± 3. Post-ablation imaging showed a technical success rate of 98 % (51 cases, 55 tumors). No major complications occurred. Follow-up imaging (26.2 ± 22.4 month) showed no local tumor progression or recurrence.
Conclusions: Use of the hepatobiliary phase for MRI-guided ablation of otherwise MR-occult tumors is a feasible approach for an effective and safe treatment of small HCC nodules.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejrad.2025.112026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma.
BMC Cancer
March 2025
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Background: Atezolizumab plus bevacizumab is recommended as a first-line treatment for unresectable hepatocellular carcinoma (uHCC). A subgroup analysis of the IMbrave150 trial showed shorter overall survival (OS) in uHCC patients with stable disease (SD) than patients with complete response (CR) or partial response (PR) after atezolizumab plus bevacizumab. Improving OS in patients with SD is an unmet medical need.
View Article and Find Full Text PDFDigital standardization in liver surgery through a surgical workflow management system: A pilot randomized controlled trial.
Langenbecks Arch Surg
March 2025
Clarunis, Department of Visceral Surgery, University Digestive Health Care Center, St. Clara Hospital and University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Introduction: Surgical process models (SPM) are simplified representations of operations and their visualization by surgical workflow management systems (SWMS), and offer a solution to enhance communication and workflow.
Methods: A 1:1 randomized controlled trial was conducted. A SPM consisting of six surgical steps was defined to represent the surgical procedure.
Quantitative Magnetic Resonance Imaging Methods for the Assessment and Prediction of Treatment Response to Transarterial Chemoembolization in Hepatocellular Carcinoma.
Acad Radiol
March 2025
Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China. Electronic address:
This article reviews the state-of-the-art applications of quantitative magnetic resonance imaging (qMRI) in predicting and evaluating response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). HCC is a highly heterogeneous tumor, and its response to TACE varies significantly among patients. Early identification of treatment response is critical for optimizing management.
View Article and Find Full Text PDFIntegrated analysis of single-cell and bulk RNA sequencing identifies APOC1 as a biomarker and therapeutic target for G0/G1 cell cycle arrest in cholangiocarcinoma.
Genomics
March 2025
Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao City, Shandong Province 266000, China. Electronic address:
Cholangiocarcinoma is characterized by its high malignancy, frequent recurrence and insensitivity to conventional radiotherapy and chemotherapy. This resistance may be associated with the presence of cells in the G0/G1 arrest phase within the cancer. Cancer cells in the G0/G1 phase are resistant to therapies targeting actively dividing cells, allowing them to evade conventional adjuvant treatments and survive.
View Article and Find Full Text PDFHBx/DTL Positive Feedback Loop Promotes HBV-Related Hepatocellular Carcinoma Progression.
J Med Virol
March 2025
Department of Pathology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China.
Although hepatitis B virus (HBV) infection is a well-documented etiologic factor for hepatocellular carcinoma (HCC), which ranks as the third leading cause of cancer-related mortality globally, the mechanism by which HBV facilitates cancer development remains largely elusive. In this study, we employed advanced methodologies including, single-cell RNA sequencing, flow cytometry, western blot analysis, chromatin immunoprecipitation-qPCR and Cut&Tag to investigate the expression of DTL and its biological functions in HCC. We observed that DTL is overexpressed in HBV-positive HCC samples, with its elevated expression being associated with increased tumor cell proliferation and reduced overall and disease-free survival rates.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!